The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for treating obesity. Unlike some existing weight loss approaches, retatrutide appears to offer a more substantial reduction in body mass and improve metabolic function, parti